THE COST-EFFECTIVENESS OF LIMB SALVAGE FOR BONE TUMOURSR. J. Grimer, FRCS, Consultant Orthopaedic Oncologist; S. R. Carter, FRCS, Consultant Orthopaedic Oncologist; and P. B. Pynsent, PhD, Director of ResearchThe Royal Orthopaedic Hospital Oncology Service, The Royal Orthopaedic Hospital, Bristol Road South, Birmingham B31 2AP, UK. Correspondence should be sent to Mr R. J. Grimer. The use of endoprostheses for limb salvage in primary bone tumours is highly specialised. Studies have shown no significant difference in survival, function or quality of life between patients with limb salvage and those with amputation. We have derived a formula for calculating the ongoing costs of limb salvage with an endoprosthesis which is based on actual costs and uses historical data to show the likelihood of further surgery or revision. Comparative data for amputation are also shown. Using current prices, the cost-effectiveness of surgery with an endoprosthesis is clearly demonstrated. This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||




